^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | eprenetapopt (APR-246) (p53 reactivator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia
Excerpt:
In a preclinical model of patient-derived TP53-mutant ALL, APR-246 reduced leukemia burden and synergized strongly with the genotoxic agent doxorubicin, leading to superior leukemia-free survival in vivo.
Secondary therapy:
doxorubicin hydrochloride
DOI:
10.3324/haematol.2018.199364
